NEXGEL, INC. (NXGL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

NEXGEL, Inc. (NASDAQ: NXGL) announced that 95% of its convertible noteholders, representing $14.125 million, agreed to convert notes into common stock, contingent on a strategic merger and other conditions. The company has secured $1.2 million in commitments, with Sequence LifeScience contributing 61%. NXGL is pursuing cost savings and a potential merger with Fountainhead LifeSciences, with a deadline of March 31, 2027.

NEXGEL (NXGL) reported Q2 2026 revenue of $3.69M, up from $2.88M a year earlier, citing Celularity transaction growth and BioNX Surgical integration. The quarter showed a net loss of $2.87M, attributed to integration costs, intangible amortization, transaction expenses, and a SilverSeal inventory recall. Shares trade around $0.39, down 30% YTD.

NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEXGEL Reports Second Quarter 2026 Financial Results LANGHORNE, Pa. – August 17, 2026 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content

HSBC is reportedly working on risk transfer deals for approximately $7B in U.S. and Asian corporate loans, with $3B in the U.S. and $4B in Asia-Pacific, according to sources.

Keurig Dr Pepper (KDP) plans a $2 billion stock offering to reduce debt before splitting into two companies in early 2027. Proceeds will repay or repurchase about $2 billion of debt. Underwriters have a 30-day option for an additional $300 million. The company reported $21.06 billion in long-term debt as of September 30, 2026. Shares fell 4% in premarket trading.

Alibaba (BABA) announced plans to spin off its AI chip unit, T-Head, via a Hong Kong IPO. The company's stock has declined 30.1% year-to-date. T-Head's valuation is estimated between $25B and $86B, with regulatory approvals pending. Alibaba's AI investment is over $53B, with negative free cash flow. T-Head competes with Nvidia, Huawei, and Baidu's Kunlunxin in China's AI market.